Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13369577 | 0.81 | NPSR1 (0.52) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL25312921 | 0.81 | NPSR1 (0.47) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL4648929 | 0.78 | SMN1; SMN2 (0.58) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL14587608 | 0.78 | NPSR1 (0.50) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL25973886 | 0.77 | L3MBTL1 (0.49) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL3390732 | 0.75 | KMT2A (0.48) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL2437732 | 0.75 | PKM (0.57) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL4002119 | 0.75 | KMT2A (0.50) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL20746019 | 0.74 | L3MBTL1 (0.58) | NPSR1L3MBTL1POLBKMT2ATHRB | |
| SCHEMBL28644530 | 0.74 | POLB (0.62) | NPSR1L3MBTL1POLBKMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| EP-4219500-A1 | CONDENSED HETEROCYCLIC COMPOUND | Nissan Chemical Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| WO-2021210586-A1 | CONDENSED HETEROCYCLIC COMPOUND | 日産化学株式会社 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | SPR, QDPR, SUCNR1 | NPSR1 103/4885L3MBTL1 2901/4885POLB 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.